ABSTRACT

This review explores the transformative potential of artificial intelligence (AI) in pharmacovigilance (PV), the field of ensuring medication safety. AI promises to significantly improve risk management, adverse drug event (ADE) detection, and signal identification. The ever-increasing volume of data from individual case safety reports (ICSRs) necessitates new approaches. Traditional methods struggle to keep pace, highlighting the critical need for AI-powered solutions. AI has the potential to revolutionise the daily work of PV professionals and accelerate career advancement. It can enhance both qualitative and quantitative aspects of PV, leading to more effective drug safety practices. By enabling advanced medical strategies like personalized treatment, AI can optimize the risk-benefit balance for patients. Additionally, AI can significantly improve signal evaluation, validation, and prioritization within PV. However, challenges remain. Legal restrictions, ethical considerations, and data quality issues require careful attention. Despite these hurdles, the future of PV is undoubtedly intertwined with AI. As AI integration progresses, we can expect substantial improvements in patient safety and pharmaceutical development. Keywords: Drug safety, Cognitive service, Pharmacology, Pharmacovigilance, Artificial Intelligence
Publication date: 01/10/2025

https://ijbpas.com/pdf/2025/October/MS_IJBPAS_2025_9526.pdf

Download PDF
https://doi.org/10.31032/IJBPAS/2025/14.10.9526